PROS1 and cystic fibrosis: The protein-folding chaperone cystic fibrosis drug, lumacaftor, was reported to inhibit viral replication in a Vero E6 cell-based SARS-CoV-2 infection assay with an IC50 of 84 μM and CC50 of 315 μM and may be a repurposed therapeutic [40].